Progenics On Way To The FDA With Second Product Offering Azedra
Progenics looks set to expand its product portfolio with a mid-year filing expected for its novel radiopharmaceutical product in ultra-rare neuroendocrine tumors following success in a pivotal study conducted under an SPA.
You may also be interested in...
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.
The latest drug development news and highlights from our US FDA Performance Tracker.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.